Pharma BD Deal Intelligence
Sanofi's ~$18.5B bid for Genzyme delivered exactly the durable rare-disease franchise it wanted—Cerezyme, Fabrazyme, and later Lemtrada gave Sanofi a lasting biologics/specialty pivot away from small-molecule exposure. The win came with a scar: a bad-faith CVR dispute over the deal's contingent payout cost Sanofi $315M in litigation.
$69 per share all-cash offer represents immediate and certain value and a significant premium for Genzyme shareholders — 38% over Genzyme's unaffected share…
Genzyme management rejected the $69-per-share hostile bid as undervalued; CEO Henri Termeer argued shareholders deserved closer to $80 per share, saying 'They…
Sanofi paid $315M to settle claims it slowed Lemtrada's development to avoid CVR payouts of $708M-$3.8B; FDA approval missed targets by 8+ months and sales…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi-aventis submitted a non-binding proposal to acquire Genzyme for approximately $18.5B ($69/share) on August 29, 2010. Final definitive agreement reached February 16, 2011 at $74/share plus CVR (~$20.1B total). Closed April 8, 2011.
Assessment window: 5yr post-close.
Gaucher and Fabry are inherited lysosomal storage disorders caused by deficient enzymes (glucocerebrosidase, alpha-galactosidase A) leading to substrate accumulation in organs. Both are ultra-rare, lifelong, and treatable only by chronic enzyme replacement therapy (ERT). Manufacturing complexity and small patient pools made Genzyme's franchise highly defensible.
At deal time (2010-2011), Genzyme dominated lysosomal storage with Cerezyme (imiglucerase) for Gaucher and Fabrazyme (agalsidase beta) for Fabry — both monopolies disrupted only by Genzyme's own 2009 Allston Landing manufacturing contamination, which created shortages and let Shire (Vpriv/velaglucerase, FDA-approved Feb 2010) and Pfizer/Protalix (Elelyso/taliglucerase, approved 2012) take share. In Fabry, Shire's Replagal (agalsidase alfa) competed ex-US but was withdrawn from US filing in 2012. Sanofi paid up specifically for the rare-disease franchise plus the MS asset Lemtrada (alemtuzumab, then awaiting FDA filing) — the CVR mechanism allocated up to $14/share in milestones tied to Cerezyme/Fabrazyme 2011 production recovery and Lemtrada approval/sales. The deal converted Sanofi from a primary-care/vaccines house into a biotech-led rare-disease leader and seeded the spinout that became Sanofi Genzyme.
Multiple sclerosis is an autoimmune demyelinating disease of the CNS that causes relapsing or progressive neurologic disability. It typically presents in adults aged 20-50 and disproportionately affects women. Disease-modifying therapies suppress relapses but do not reverse existing damage.
In 2010-2011, the MS market was dominated by interferon-betas (Avonex/Biogen, Rebif/Merck KGaA-Pfizer, Betaseron/Bayer) and Copaxone (glatiramer/Teva), with Tysabri (natalizumab, Biogen-Elan) carving the high-efficacy niche despite PML risk. Novartis' Gilenya (fingolimod) had just become the first oral DMT (Sept 2010), and Biogen's Tecfidera (dimethyl fumarate) was approaching filing. Genzyme's Lemtrada (alemtuzumab) — already marketed at higher doses as Campath in CLL — was being repositioned as an induction-style anti-CD52 antibody promising long-lived remission from short dosing courses. Sanofi structured the CVR specifically because buy- and sell-side disagreed sharply on Lemtrada's commercial peak; the FDA ultimately rejected the first BLA in late 2013 before approving in Nov 2014 with a restricted REMS, validating analyst skepticism and triggering a decade of CVR litigation that Sanofi settled for $315M in 2019.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Genzyme Corporation (this deal) | 2010 | $18.5B | 75 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 2010 deals · Sanofi SA deals · Neurology deals